Immunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 Study
22 Mayo 2023 - 10:50AM
Noticias Dow Jones
By Colin Kellaher
Immunovant shares hit a new 52-week high Monday after the
clinical-stage immunology company said it received U.S. Food and
Drug Administration approval to conduct a Phase 1 study of its
IMVT-1402 drug candidate for autoimmune disease.
Shares of the New York company were recently changing hands at
$23.94, up nearly 13%, after touching a 52-week high of $24.19
earlier in the session.
Immunovant said the study will evaluate the safety, tolerability
and pharmacodynamic profiles of IMVT-1402 in healthy
volunteers.
The company said it expects initial data from single-ascending
dose cohorts in August or September, with initial data from
multiple-ascending dose cohorts in October or November 2023.
Immunovant said IMVT-1402 has been observed to achieve similarly
deep Immunoglobulin G reduction as batoclimab, the company's lead
drug candidate, in a head-to-head, placebo-controlled nonclinical
study, with have minimal or no impact on levels of albumin and
low-density lipoprotein cholesterol at doses well above the
anticipated human effective dose, adding that it believes this
profile could be best-in-class.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 22, 2023 11:35 ET (15:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Immunovant (NASDAQ:IMVT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immunovant (NASDAQ:IMVT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024